The role of mitochondria dynamics and its molecular regulators remains largely unknown during naïve-to-primed pluripotent cell interconversion. Here we report that mitochondrial MTCH2 is a regulator of mitochondrial fusion, essential for the naïve-to-primed interconversion of murine embryonic stem cells (ESCs). During this interconversion, wild-type ESCs elongate their mitochondria and slightly alter their glutamine utilization. In contrast, MTCH2 −/− ESCs fail to elongate their mitochondria and to alter their metabolism, maintaining high levels of histone acetylation and expression of naïve pluripotency markers. Importantly, enforced mitochondria elongation by the pro-fusion protein Mitofusin (MFN) 2 or by a dominant negative form of the pro-fission protein dynamin-related protein (DRP) 1 is sufficient to drive the exit from naïve pluripotency of both MTCH2 −/− and wild-type ESCs. Taken together, our data indicate that mitochondria elongation, governed by MTCH2, plays a critical role and constitutes an early driving force in the naïve-to-primed pluripotency interconversion of murine ESCs.
P luripotency pertains to the potential to differentiate into all three embryonic germ layers 1 . In vitro naïve pluripotency refers to embryonic stem cells (ESCs) derived from the inner cell mass of pre-implantation mouse blastocysts at E3.5, whereas in vitro primed pluripotency is represented by epiblast stem cells (EpiSCs) commonly derived from the late epiblast layer of post-implantation mouse embryos at E5.5-E6.5. These two cell types differ in their morphology, cytokine dependence, gene expression and epigenetic and metabolic profiles 2, 3 .
Reprogramming of mitochondria metabolism plays a critical role in the naïve-to-primed interconversion [4] [5] [6] [7] [8] [9] [10] [11] [12] . Importantly, this interconversion is accompanied by the elongation of the mitochondria and a pronounced metabolic switch to a highly glycolytic state with a low mitochondrial respiratory capacity 11 , suggesting a role for mitochondria that is distinct from energy production. Mitochondria dynamics, which represents a central mechanism for cell identity and fate decisions [13] [14] [15] [16] [17] , could potentially contribute to mitochondria enlargement and naïve-toprimed interconversion of ESCs. The critical cellular roles of mitochondrial dynamics during the early stages of embryogenesis are underscored by the observation that loss of mitochondria fusion results in embryonic lethality in midgestation 18, 19 .
Mitochondrial carrier homolog 2 (MTCH2) is a regulator of mitochondrial apoptosis and metabolism that plays a critical role in controlling the quiescence/cycling of hematopoietic stem cells (HSCs) [20] [21] [22] . We previously demonstrated that loss of MTCH2 results in embryonic lethality that is completed by E7.5 20 . Intriguingly, loss of MTCH2 also results in changes in mitochondria morphology [21] [22] [23] , suggesting that MTCH2 may play a role in regulating mitochondrial dynamics during embryogenesis. Here we show that mitochondria elongation, governed by MTCH2, plays a critical role and constitutes an early driving force in the naïve-to-primed pluripotency interconversion of murine ESCs.
Results
MTCH2 is a regulator of mitochondrial fusion. Our initial studies of the potential role of MTCH2 in mitochondrial dynamics were performed in mouse embryonic fibroblasts (MEFs), in which changes in mitochondria morphology are readily visualized. These studies demonstrated that knocking out MTCH2 in MEFs using Cre recombinase in vitro results in a lesselongated/round mitochondria morphology (Fig. 1a , top left and right panels, respectively), which was quantified by morphological classification (bottom left panel), aspect ratio calculation (bottom right panel), and sphericity (three-dimensional (3D) structural analysis of mitochondria using computerized segmentation; Fig. 1b ). Importantly, the less-elongated/fragmented mitochondria morphology in the MTCH2 −/− cells was rescued by the expression of MTCH2-GFP ( Fig. 1c ; 84.6% rescue of cells with elongated mitochondrial network as compared to MTCH2 F/F ). Next, we performed a mitochondria fusion assay using a photoactivatable GFP protein targeted to the mitochondria matrix 24 , and found that MTCH2 −/− mitochondria exhibit a lower fusion rate (slower spreading of the GFP; Fig. 1d ). To confirm that increased mitochondrial fragmentation is indeed caused by a decrease in mitochondrial fusion, we expressed MFN2, a critical regulator of mitochondria fusion, in MTCH2 −/− MEFs. Similar to the case of re-expression of MTCH2, MFN2-Myc decreased the mitochondria fragmentation ( Fig. 1e ; 86.1% rescue of cells with elongated mitochondrial network as compared to MTCH2 F/F ). Importantly, loss of MFN2, which results in complete fragmentation of mitochondria 18 , was largely rescued by the expression of MTCH2-GFP (Fig. 1f ), a finding that is consistent with the idea that MTCH2 is an important regulator of mitochondria fusion.
MTCH2 loss in ESCs results in mitochondrial fragmentation. Since MTCH2 knockout results in embryonic lethality by E7.5 20 , we next asked whether this lethality is possibly due to a mitochondrial defect already present at E3.5, which could be studied in ESCs. We initially crossed MTCH2 +/− mice and found that blastocysts grown in 2i (MEKi and GSK3i)/LIF (2i/L) yielded MTCH2 −/− ESCs at a ratio lower than expected ( Fig. 2a ). Also, knockout of MTCH2 in MTCH2 F/F naïve ESCs using Cre recombinase in vitro led to slower cell growth ( Fig. 2b ) with no effect on the basal levels of apoptosis ( Supplementary Fig. 1a ). Furthermore, MTCH2 −/− ESCs preserved their naïve pluripotency, as evident from normal transcription levels of naïve core pluripotency markers ( Supplementary Fig. 1b ). We also tested the growth and differentiation capacity of these cells by assessing their ability to generate teratomas in vivo. Indeed, while the tumors obtained from the MTCH2 −/− ESCs were smaller in size ( Fig. 2c ), they were able to differentiate properly to all three germ layers ( Supplementary Fig. 1C ). These findings indicate that MTCH2 deletion in ESCs does not compromise naïve pluripotency.
Next, we analyzed the morphology of mitochondria and found, similar to our findings in MEFs, that loss of MTCH2 results in a less-elongated/round mitochondria morphology ( Fig. 2d ), which was quantified by sphericity ( Fig. 2e ) and by aspect ratio (Fig. 2f ). We also performed a mitochondria fusion assay, using ESCs prepared from genetically engineered mice with photo-activatable/convertible mitochondria (PhAM; green-to-red) 25 crossed to MTCH2 F/F mice, and confirmed that MTCH2 −/− mitochondria exhibit a lower fusion rate (slower decrease in red fluorescence protein (RFP) intensity; Supplementary Fig. 2A ).
In an attempt to obtain insights into the molecular basis of the observed mitochondrial morphology changes in MTCH2 −/− ESCs, we monitored the expression levels of the major mitochondria dynamics regulators in MTCH2 F/F and MTCH2 −/− naïve ESCs. Western blot analysis of whole-cell lysates and of mitochondria/ cytosol fractions indicated that there is no significant differences in the expression levels of most of these proteins between the MTCH2 F/F and MTCH2 −/− cells ( Supplementary Fig. 2B , C). Notably, there was a decrease in MFN1 and OPA1 levels in all three MTCH2 −/− clones, but this decrease was accompanied by a decrease in TOM20 levels, which may indicate a reduction in mitochondria mass.
Notably, previous studies have shown that defects in mitochondria fusion lead to hyper-fragmentation of mitochondria, which, in turn, results in destabilization of mitochondrial DNA (mtDNA) and a decrease in mitochondrial function 26 . Indeed, we found that loss of MTCH2 in ESCs leads to a reduction in both mtDNA copy number ( Fig. 2g ) and mitochondria respiration (Fig. 2h ). The above results are consistent with the idea that MTCH2 deletion in ESCs results in mitochondria hyper-fragmentation and decreased mitochondrial function, which lead to slower growth of ESCs and to a decrease in E3.5 derivation efficiency.
We previously reported that mitochondria respiration/function increases upon MTCH2 deletion in HSCs and skeletal muscle cells 21, 22 . We hypothesize that loss of MTCH2 in these cells initially results in a decrease in mitochondria respiration/function (as seen in ESCs), and the increase observed is a compensatory mechanism to correct for the defect and keep the cells alive. In the case of ESCs, we hypothesize that increasing mitochondria respiration/function may not be sufficient to enable normal embryonic development, and thus the mitochondrial defect is not corrected and the embryos eventually die at E7.5.
MTCH2 loss delays exit from naïve pluripotency. The mitochondria of wild-type primed EpiSCs shift towards a more elongated state than those of naïve ESCs 11 , suggesting that mitochondria fusion/elongation may play a role in the naïve-toprimed transition. Recent studies have demonstrated that in vitro priming for a period of 2 days of ground-state pluripotent ESCs (using Activin A/fibroblast growth factor 2 (FGF2); AF) generates pre-gastrulation epiblast-like cells (EpiLCs) that most closely resemble the in vivo counterpart E5.75 epiblasts 2 . Thus, to test our hypothesis that mitochondria fusion/elongation via MTCH2 is important for the naïve-toprimed interconversion, we utilized the ESCs-to-EpiLCs system. We monitored the morphology of mitochondria during the interconversion from ESCs to EpiLCs and found that the mitochondria of primed MTCH2 F/F cells were more elongated and also showed a steeper aspect-ratio increase as compared to the mitochondria of MTCH2 −/− cells ( Fig. 3a ).
Since mitochondria dynamics represents a central mechanism for metabolic regulation 16, 19 , we also assessed whether metabolic changes accompany the naïve-to-primed interconversion. We measured the changes in metabolites' carbon labeling following 6 h of incubation with uniformly labeled 13 C substrates (as it was shown that isotopic equilibrium is reached by this time point in mouse ESCs 4 ). Using gas-chromatography mass-spectrometry, we found that in MTCH2 F/F EpiLCs there is a 10% decrease in relative glucose utilization and a corresponding increase in relative glutamine utilization for replenishing TCA-cycle metabolites ( Fig. 3b , left and right panels, respectively). Notably, the labeling of citrate from glucose or directly from pyruvate only marginally changed after priming ( Fig. 3b , left panel, and Supplementary Fig. 3A , respectively). Importantly, we found that the increase in relative glutamine utilization following priming of the MTCH2 F/F cells is more pronounced than in the MTCH2 −/− cells ( Fig. 3c and Supplementary Fig. 3B ), suggesting that MTCH2 plays a role in regulating this metabolic shift during the naïve-to-primed transition.
A previous study demonstrated that modulating the levels of acetyl-CoA and histone acetylation during the early differentiation of PSCs is essential for differentiation, pointing out that blocking histone deacetylation delays the exit from pluripotency 7 .
To determine whether the inability of MTCH2 −/− EpiLCs to properly alter their metabolism during priming correlates with histone acetylation levels, we assessed the changes in the levels of acetylated histone 3 (H3) by Western blot analysis. Interestingly, MTCH2 F/F EpiLCs show robust H3 deacetylation while MTCH2 −/− EpiLCs maintain high levels of H3 acetylation, comparable with the H3 acetylation levels seen in the naïve state ( Fig. 3d ). These results are consistent with the idea that MTCH2, via regulation of mitochondria morphology/metabolism, regulates epigenetic mechanisms. In an attempt to find a causal link between the metabolic results described above and the epigenetic results, we measured Acetyl-CoA (Ac-CoA) levels in whole-cell lysates but did not find any differences between the MTCH2 F/F and MTCH2 −/− naïve and primed cells ( Supplementary Fig. 3C ).
To assess whether the mitochondrial morphology/metabolism and epigenetic alterations in the MTCH2 −/− EpiLCs also delay the exit from naïve pluripotency, we performed a genome-wide transcriptomic analysis with RNA-Seq. The analysis was performed on four groups of cells: MTCH2 F/F cells grown in either 2i/L (ESCs) or in AF (EpiLCs) conditions, and MTCH2 −/− cells grown in either 2i/L (ESCs) or in AF (EpiLCs) conditions. Hierarchical clustering and principal component analysis (PCA) based on differentially expressed (DE) genes between the four groups showed that while the MTCH2 F/F ESCs and EpiLCs are distinct sub-populations of cells, MTCH2 −/− ESCs and EpiLCs are clustered together and not with MTCH2 F/F cells (Fig. 3e ). These results suggest that priming has a dampening effect on the MTCH2 −/− cells. Moreover, genes associated with either stem cell maintenance or stem cell differentiation (Fig. 3f , left and right panels, respectively) show large changes in AF versus 2i/L in MTCH2 F/F cells (left columns in both panels) as opposed to relatively small or no changes in MTCH2 −/− cells (right columns in both panels; note the many black lines that represent no difference).
To validate the RNA-Seq results, we utilized qPCR of known pluripotency and developmental genes regulated during priming. We found that MTCH2 −/− EpiLCs failed to reduce the expression of naïve pluripotency genes and to adequately regulate the levels of developmental genes (Fig. 3g , top and lower panels, respectively). To confirm these changes at the protein level, we analyzed the levels of the naïve marker Nanog by immunostaining. While there was no difference in Nanog expression levels between MTCH2 F/F and MTCH2 −/− ESCs grown in 2i/L ( Fig. 3h , top six pictures), its levels were extremely reduced in MTCH2 F/F EpiLCs, whereas MTCH2 −/− EpiLCs maintained relatively high expression levels of Nanog (Fig. 3h , bottom six pictures).
Mitochondria elongation drives exit from naïve pluripotency.
To determine whether mitochondria fusion/elongation constitutes an early driving force in the naïve-to-primed pluripotency interconversion of ESCs, we tested whether rescuing the mitochondria's hyper-spherical/fragmented morphology in MTCH2 −/− naïve ESCs by expressing MFN2-Myc would, in turn, restore exit from naïve pluripotency. Strikingly, MTCH2 −/− naïve ESCs expressing MFN2-Myc showed repression of nuclear Nanog expression levels ( Fig. 4a ; see images in the left panels and bar graph in the top right panel). Importantly, in cells expressing MFN2-Myc there was a correlation between the increase in elongated mitochondria (increase in aspect ratio of mitochondria) and the decrease in Nanog expression levels (decrease in nuclear Nanog intensity; Fig. 4a , bottom right panel). We also determined the expression levels of estrogen receptor related β (ESRRβ), a downstream target of Naong and a key regulator of mouse naïve pluripotency 27 , and found that Most importantly, the expression of MFN2-Myc in MTCH2 F/F naïve ESCs, maintained in naïve 2i/L conditions, also repressed nuclear Nanog expression levels (Fig. 4c ). In the MTCH2 F/F naïve ESCs expressing MFN2-Myc there was also a correlation between the increase in elongated mitochondria and the decrease in Nanog expression levels (Fig. 4c, bottom (Fig. 4d ). In the MTCH2 F/F naïve ESCs expressing MFN2-Myc there was also a correlation between the increase in elongated mitochondria and the decrease in ESRRβ expression levels (Fig. 4d, bottom right panel) .
To assure that the changes in Nanog and ESRRβ expression levels were not due to a non-specific effect or to complete differentiation into a somatic lineage, we validated the expression levels of Oct-4, a pluripotent gene marker whose expression levels remain high during the naïve-to-primed interconversion 28 . We found that in MTCH2 F/F naïve ESCs expressing MFN2-Myc and possessing elongated mitochondria, Oct-4 levels were only slightly reduced (Fig. 4e ). Relative densitometry (a.u.)
2i/l 2i/l AF AF To distinguish the importance of active fusion per se from an elongated network for the exit from naïve pluripotency, we tested whether prompting the elongation of mitochondria by expressing a dominant negative form of the pro-fission protein dynamin-related protein 1 (DRP1-dn-YFP) would also induce exit from naïve pluripotency. We found that MTCH2 F/F and MTCH2 −/− naïve ESCs expressing DRP1-dn-YFP showed elongated mitochondria and repression of both Nanog and ESRRβ expression Supplementary Fig. 4A -D; see images in the left panels and bar graphs in the right panels; note that DRP1-dn-YFP appears in green and is marked by white arrows in the top left images). Thus, active fusion per se is not required but rather an elongated network for the exit from naïve pluripotency.
Discussion
Our studies reveal an unanticipated feature for mitochondria elongation in the naïve-to-primed interconversion of ESCs (Fig. 4f ). We demonstrate that enforced elongation of mitochondria in naïve ESCs, even without eliminating the 2i/L conditions, is sufficient to trigger partial exit from naive pluripotency without entering differentiation, since the naïve markers Nanog and ESRRβ are repressed but Klf4 is not and the differentiation markers T-brachyury and FOXA2 are not expressed ( Fig. 4 and Supplementary Fig. 5 ). These findings possibly relate to the recently described "Formative Pluripotency Phase", an intermediate phase proposed to exist as part of a developmental continuum between the naïve and primed pluripotent states, marked by the downregulation of only part of the essential transcription factor program that maintains naïve pluripotency 29, 30 . Moreover, induction of lineage-specific markers was not evident in the formative phase, suggesting that terminating the naïve circuitry precedes the expression of lineage markers 31 .
Our studies also show that MTCH2 is a direct regulator of mitochondrial fusion/elongation in both MEFs and ESCs, capable of rescuing the mitochondrial structure of MFN2-deficient cells. In ESCs, MTCH2 is important for altering glucose and glutamine utilization, histone deacetylation and nuclear gene reprogramming during the naïve-to-primed interconversion. However, further studies are required to elucidate the exact mechanism by which MTCH2 regulates mitochondria fusion/elongation and the metabolic-epigenetic link.
The finding that enforced elongation of mitochondria is sufficient for nuclear gene reprogramming is consistent with the idea that mitochondria elongation drives reprogramming of mitochondria metabolism, which, in turn, leads to histone deacetylation and changes in gene transcription ( Fig. 4f ; see dotted lines). Thus, mitochondria elongation, in which MTCH2 plays a critical role, is a necessary and early event important for naïve ESCs to adequately exit from the ground state of pluripotency.
Methods
Stem cell lines and cell culture. Growth of primary murine pluripotent stem cells was conducted in FBS free N2B27-based media as described previously 32 . Briefly, 500 ml of N2B27 media was generated by including: 250 ml DMEM/F12 (HEPES free, custom made; Biological Industries), 250 ml Neurobasal (cat # 21103; Invitrogen), 2.5 ml N2 supplement (cat # 17502048; Invitrogen), 5 ml B27 supplement (cat # 17504044; Invitrogen), 1 mM glutamine (Invitrogen), 1% nonessential amino acids (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma), penicillin-streptomycin (Invitrogen), 5 mg/ml BSA (Sigma). Naïve conditions for murine ESCs included 10 μg recombinant human LIF (L; Peprotech) and small-molecule inhibitors CHIR99021 (CH, 3 μM; Axon Medchem) and PD0325901 (PD, 1 μM; TOCRIS) termed 2i. Primed conditions for murine EpiLCs contained 8 ng/ml recombinant human bFGF (FGF2; Peprotech), 20 ng/ml recombinant human Activin A (Peprotech), and 1% knockout serum replacement (KSR; Invitrogen), in feeder-free growth factor reduced matrigel (Corning)-coated wells. For maintenance and Cre recombinase treatment, ESCs were kept in FBS/2i/L growth conditions, expanded in 500 ml of high-glucose DMEM (Invitrogen), 15% USDA certified fetal bovine serum (FBS; Biological Industries), 1 mM glutamine (Invitrogen), 1% nonessential amino acids (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma), penicillinstreptomycin (Invitrogen), 10 μg recombinant human LIF (Peprotech) with 2i, on irradiation-inactivated mouse embryonic fibroblast (iMEF) feeder cells. Cells were maintained in 20% O 2 conditions and were passaged following 0.25% trypsinization (Invitrogen). Cell counts and growth curves were conducted using a hemacytometer (Sigma). MEFs were maintained in high glucose DMEM 10% FBS supplemented with glutamine, sodium pyruvate, and antibiotics.
ESC derivation and MEF preparation. The Weizmann Institute Animal Care and Use Committee approved all animal experiments. MTCH2 heterozygous or MTCH2 homozygous conditional knockout mice (MTCH2 F/F ) (C57BL/6J strain; 20 ) were crossed and E3.5 embryos were flushed and transferred onto iMEF-coated 96well plates and cultured in FBS/2i/L conditions. Established ESC clones were genotyped by PCR and validated as MTCH2-deficient by qPCR and by Western blot analysis. MTCH2 F/F mice were crossed to the PhAM mice 25 to generate MTCH2 F/F PhAM mice carrying the mito-dendra2 transgene, and ESCs were prepared from these mice as described above. MTCH2 F/F primary MEFs were prepared from 11 to 13-day-old embryos and transformed with the SV40 whole genome as described previously 33 . All the studies with MEFs described in the paper were performed with SV40-immortalized MEFs. Primer sequences used for genotyping are listed below:
MTCH2 WT F-5′-TGTTCACAGGCTTGACTCCA-3′ MTCH2Δ F-5′-TCCCAAGTGCTGGATTAAGG-3′ MTCH2 WT/Δ R-5′-CAAACTGTATAGGTGAATGGCTCT-3′.
In vitro naïve-to-primed pluripotent cell conversion. For conversion of murine naïve pluripotent ESCs into primed EpiLCs, naïve ESCs were seeded in feeder-free N2B27 2i/L conditions for 16-24 h before switching to N2B27 Activin A/FGF2 (A/F) conditions for 2 days.
Poly-A RNA sequencing. Total RNA was extracted from the indicated cell cultures using PerfectPure RNA-cultured cell kit (cat # 2302340, 5′). To avoid DNA contaminations all samples were treated with DNase (5 prime 35 . Per gene reads were counted using HTSeq 36 . Normalization of read counts and p-values for differential expression genes were computed using Deseq2 37 . Stem cell maintenance and developmental markers of DE genes were filtered using gene ontology consortium enrichment analysis.
Histone isolation. Histones were isolated by acid extraction as described previously 38 and were resolved (8.0-10 µg of histones) by 15% SDS-PAGE. Briefly, cells were suspended with NP-40 lysis buffer (10 mM Tris-Cl, [pH 7.6], 150 mM NaCl, 1.5 mM MgCl 2, 0.65% NP-40, 5 mM protease inhibitor) and homogenized, followed by 5000 r.p.m. centrifugation for 10 min at 4°C. Cell pellets were resuspended in RSB buffer (10 mM Tris-Cl, [pH 7.4], 3 mM MgCl 2 , 10 mM NaCl, 5 mM protease inhibitor) and homogenized, followed by the addition of 0.4 N H 2 SO 4 for 1 h rotation in 4°C. Samples were then centrifuged in 10,000 r.p.m. for 20 min at 4°C and supernatant was added with 100% TCA to a final concentration of 18%. Samples were left on ice for 20 min, followed by centrifugation and washing the cell pellet once in acetone/HCl (5 µl acid/ml acetone) and twice solely in acetone followed by air-drying the pellets overnight and resuspention in water. Western blots were analyzed using anti-acetylated-H3 (cat # 06-599; Millipore) and anti-H3 (cat # 4499; Cell signaling) antibodies.
Western blot and subcellular fractionation. Subcellular fractionations were performed as described previously 20, 39 . Briefly, cells were suspended in isotonic HIM buffer (200 mM mannitol, 70 mM sucrose, 1 mM EGTA, 10 mM HEPES (pH 7.5)). The supernatant was centrifuged at 10,000×g for 10 min to collect the mitochondrion-enriched fraction and the supernatant (cytosol). Proteins were size fractionated by SDS-PAGE and then transferred to polyvinylidene difluoride membranes. Antibodies used for Western blotting included anti-MTCH2 1:1000 20 , anti-adenine nucleotide translocator 1:1000 (ANT; cat # SC-9300; Santa Cruz), and anti-succinate dehydrogenase A 1:1000 (SDHA; Ab 14715; Invitrogen), mouse anti-OPA1 1:1000 (cat # 612606; BD biosciences), mouse anti-MFN1 1:1000 (cat # NBP1-71775; Novus biologicals), mouse anti-MFN2 1:1,000 (cat # WH0009927M3; Sigma-Aldrich), mouse anti-DRP1 1:1000 (cat # 611112; BD biosciences), rabbit anti-pDRP1 S637 1:1000 (cat # 4867; Cell signaling), anti-TOM20 1:1000 (cat # SC-11415; Santa cruz), and anti-actin 1:10,000 (cat # A5441; Sigma). The uncropped scans of the blots presented in Fig. 3d appear in Supplementary  Fig. 6 .
Quantitative PCR. Total RNA was isolated using PerfectPure RNA cultured cell kit (5 prime), and gDNA was omitted by on-column DNase treatment. One microgram of RNA was reverse-transcribed using HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems). To evaluate mtDNA copy number, total DNA was isolated using Epicentre MasterPure DNA purification kit. To avoid RNA contaminations all samples were treated with RNase A (MasterPure). Quantitative PCR analysis was performed in triplicate for each sample by using 10 ng of the reverse transcription reaction in a Viia7 platform (Applied Biosystems) with Fast SYBR ® Master Mix (Applied Biosystems). Data was extracted from the linear range of amplification. Error bars indicate standard deviation of triplicate measurements of three biological samples. Primer sequences used for all the genes tested are listed below:
Teratoma formation assay. For teratoma generation, 5 × 10 6 ESCs were injected subcutaneously into both flanks of recipient NSG immuno-deficient mice. Four weeks after initial injection tumors were harvested for paraffin embedding and sectioning followed by H&E staining.
Respiration. Measurement of intact cellular respiration was performed using the Seahorse XF24 analyzer (Seahorse Bioscience Inc.) and the XF Cell Mito Stress Test Kit according to manufacturer's instructions and as described 40 . Respiration was measured under basal conditions, and in response to Oligomycin (ATP synthase inhibitor; 0.5 μM) and the electron transport chain accelerator ionophore FCCP (trifluorocarbonylcyanide phenylhydrazone; 1 μM) to measure the maximal oxygen consumption rate (OCR). Finally, respiration was stopped by adding the electron transport chain inhibitor Antimycin A (1 μM).
Cre recombinase treatment. Recombinant His-TAT-NLS-Cre (Cre recombinase) fusion protein was expressed and purified as described previously 41 . Cre recombinase was diluted in DMEM/PBS to a final concentration of 3 µM, sterile-filtered, and incubated with the cells for 16 h. The cells were then washed with PBS, supplemented with growth medium, and grown for an additional 3-5 days before use in experiments.
Expression of plasmids and transfections. The MTCH2-GFP plasmid was generated in our laboratory and was previously described 39 Aspect ratio of mitochondria calculations. Aspect ratio (the ratio between the major and minor axis of the ellipse) was calculated using FIJI software. Z-stacks of cells stained for the mitochondrial marker TOM20 were processed and thresholded (binarized) to run the analyzed particles algorithm and calculate aspect ratio of each mitochondria.
Analysis of Nanog, ESRRβ, and Oct-4 nuclear expression levels in images. Analysis of Nanog, ESRRβ, and Oct-4 mean fluorescence intensity was performed on Z projections of z-stack pictures of ESCs transfected with MFN2-Myc. Nuclei perimeters were drawn using the FIJI poligon tool, and mean fluorescent intensity was measured in arbitrary units for each of the different regions of interest.
Average fluorescence intensity was calculated for cells expressing MFN2-Myc and cells with no detectable expression of the protein. To calculate the correlation between aspect ratio of mitochondria and nuclear Nanog, ESRRβ or nuclear Oct-4 fluorescence intensities, each MFN2-Myc-expressing cell was analyzed separately.
Using the fluorescence intensity of the MFN2-Myc channel we performed aspect ratio analysis of mitochondria as described above. Then the mean nuclear fluorescence intensity of either Nanog or Oct-4 in the MFN2-Myc-expressing cell was measured and analyzed together with its average aspect ratio value.
Mitochondria 3D reconstruction and morphometric analysis. Cells were fixed and mitochondria was stained as described above. All the images were taken under the same conditions of laser power and exposure time. Z-stack interval was set to 0.24 µm and a 3D deconvolution algorithm was applied to the ESCs images using Autoquant software (MediaCybernetics). Mitochondrial 3D reconstruction was achieved using segmentation algorithm of Imaris software (Bitplane).
Quantification of mitochondrial fusion rate in MEF. For quantification of mitochondrial fusion rate in MEF, 2 × 10 5 cells seeded onto 24-mm round glass plates were transfected with mito-pAGFP. After 24 h, cells were placed on the stage of a spinning disc microscope coupled to a FRAP unit (Zeiss 710). To activate the PA-GFP fluorescence, 1z plane was activated using 100% of the power of the 405 nm laser line with a ×100, 1.4 NA objective. Frames were then acquired every 20 min using the 488 nm and the 563 laser. Intensity of the green fluorescence was measured in the initially photoactivated ROI through time. Mitochondria were stained using 50 nM Mitotracker CMXRos (Molecular Probes, Inc.).
Quantification of mitochondrial fusion rate in ESCs prepared from MTCH2F/F PhAM mice. For these experiments we used genetically engineered mice with photo-activatable mitochondria (PhAM) 25 . These mice express mito-dendra2, a mitochondria matrix-targeted green-to-red photoconvertible fluorescent protein, in which mitochondria are constantly green, and laser excitation converts the excised population of mitochondria to become red. PhAM mice were crossed to MTCH2 F/F mice to generate MTCH2 F/F PhAM mice, and quantification of mitochondrial fusion rate was analyzed by fluorescence spreading in ESCs prepared from these mice. Mito-dendra2 was exposed to 405 nm laser light irreversibly switching green fluorescent mitochondria to red fluorescent mitochondria. Images were acquired every 30 min with a Zeiss Yokogawa spinning disc scanning unit coupled with an inverted IX83 microscope (Olympus), using a ×100 oil lens (NA 1.4) and capturing the images with sCMOS 4. Metabolomics analysis. End-point analysis of metabolites using gas chromatography-mass spectrometry (GC-MS) was performed as previously described 42 . Briefly, ESCs were incubated with either 10 mM of D-glucose (cat # CLM-1396; U-13 C 6 , 98%, Cambridge Isotope Laboratories) or 4 mM of L-glutamine (cat # CLM-1822; U-13 C 5 , 98%, Cambridge Isotope Laboratories) or 10 mM of sodium pyruvate (cat # CLM-2440; U-13 C 3 , 98%, Cambridge Isotope Laboratories) for 6 h. Subsequently, cells were washed with ice-cold saline, lysed with 50% methanol in water and quickly scraped followed by three freeze-thaw cycles in liquid nitrogen. The insoluble material was pelleted in a cooled centrifuge (4°C) and the supernatant was collected for consequent GC-MS analysis. Samples were dried under air flow at 42°C using a Techne Dry-Block Heater with sample concentrator (Bibby Scientific) and the dried samples were treated with 40 μl of a methoxyamine hydrochloride solution (20 mg/ml in pyridine) at 37°C for 90 min
